In Scotland, a newly licensed medicine is routinely available in a health board only after it has been:

- accepted for use in NHS Scotland by the Scottish Medicines Consortium (SMC), and
- accepted for use by the health board's Area Drug and Therapeutics Committee (ADTC).

All medicines accepted by SMC are available in Scotland, but may not be considered 'routinely available' within a particular health board because of available services and preferences for alternative medicines.

'Routinely available' means that a medicine can be prescribed by the appropriately qualified person within a health board.

Each health board has an ADTC. The ADTC, Grampian Area Drug and Therapeutics Committee, is responsible for advising NHS Grampian health board on all aspects of the use of medicines.

Medicines routinely available within NHS Grampian are usually included in the Grampian Joint Formulary. The formulary is a list of medicines for use in the health board that has been agreed by the ADTC in consultation with local clinical experts. It offers a choice of medicines for healthcare professionals to prescribe for common medical conditions. A formulary can help improve safety as prescribers are likely to become more familiar with the medicines in it and also helps make sure that standards of care are consistent across the health board.

How does the health board decide which new medicines to make routinely available for patients?

The ADTC in a health board will consider national and local guidance before deciding whether to make a new medicine routinely available.

What national guidance does the ADTC consider?

- SMC advice: The SMC considers newly licensed medicines and advises health boards in Scotland whether they should be available. When SMC considers a new medicine for the NHS in Scotland, it looks at:
  - how well the medicine works,
  - which patients might benefit from it,
  - whether it is as good or better than medicines the NHS already uses to treat the medical condition, and
  - whether it is good value for money.
- In the table below, national guidance usually refers to SMC advice. Links to SMC advice for individual medicines are also included in the table.
- In some cases, other agencies may also provide guidance on how medicines should be used. For example, Healthcare Improvement Scotland issues alerts to advise if National Institute for Health and Care Excellence Multiple Technology Appraisals (NICE MTAs) are applicable in Scotland.

What local guidance does the ADTC consider?

- Advice from local clinical experts who would be expected to prescribe a particular medicine, where that service is available in a health board.

Why is a particular medicine not routinely available in NHS Grampian?

- This is usually because the medicine is not recommended for use in NHS Scotland by the SMC.
- The medicine may not be routinely available in a health board, particularly in smaller health boards, because there is not a suitable specialist who may use the medicine.
- There may also be differences as to which medicines are preferred in health boards. Sometimes SMC accepts more than one medicine for treating a specific medical condition. Clinical experts in each health board consider whether to add new medicines to their formulary and advise the ADTC. Sometimes it is agreed that established medicines are a better choice than new medicines.

What happens if a particular medicine is not routinely available in NHS Grampian?

- If a medicine is not routinely available and not included in the Grampian Joint Formulary and there are no suitable alternatives on the formulary, a healthcare professional can request to prescribe a medicine that is not on the formulary if they think you will benefit from using it. All health boards have procedures in place to consider requests when a healthcare professional feels a medicine that is not on the formulary would be right for a particular patient.

The table below lists NHS Grampian's latest decisions on medicines.

If you need more information on medicines decisions in NHS Grampian, please email gram.formularyteam@nhs.scot.



This document is also available in large print and other formats and languages, upon request. Please call NHS Grampian Corporate Communications on (01224) 551116 or (01224) 552245.

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
abaloparatide 80microgram solution for injection in pre-filled pen (Eladynos®)	2764	Treatment of osteoporosis in postmenopausal women with a very high risk of fracture, assessed using a validated fracture risk assessment tool.	Routinely available in line with national guidance, SMC 2764 https://scottishmedicines.org.uk/media/9258/abaloparatide-eladynos-final-june-2025-amended-250625-for-website.pdf	21/04/2026
acalabrutinib 100mg film-coated tablets (Calquence®)	2893	In combination with venetoclax with or without obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL). **SMC restriction**: acalabrutinib in combination with venetoclax only.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	21/04/2026
Alyftrek® 50mg/20mg/4mg, 125mg/50mg/10mg film-coated tablets (deutivacaftor/ tezacaftor/ vanzacaftor)	2800	For the treatment of cystic fibrosis (CF) in people aged 6 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.	Routinely available in line with national guidance, SMC 2800 https://scottishmedicines.org.uk/media/9886/vanzacaftor-alyftrek-abb-final-feb-2026-for-website.pdf	21/04/2026
baloxavir marboxil 40mg, 80mg film-coated tablets (Xofluza®)	2920	Treatment of uncomplicated influenza in patients aged 3 weeks and above.	Not routinely available as not recommended for use in NHS Scotland, SMC 2920 https://scottishmedicines.org.uk/media/9972/baloxavir-marboxil-xofluza-smc2920-non-sub-final-march-2026-for-website.pdf	21/04/2026
baloxavir marboxil 40mg, 80mg film-coated tablets (Xofluza®)	2921	Post-exposure prophylaxis of influenza in individuals aged 3 weeks and above.	Not routinely available as not recommended for use in NHS Scotland, SMC 2921 https://scottishmedicines.org.uk/media/9973/baloxavir-marboxil-xofluza-smc2921-non-sub-final-march-2026-for-website.pdf	21/04/2026
bosentan 62.5mg, 125mg tablets	465/24	For the treatment of digital ulceration in systemic sclerosis in adults.	Routinely available in line with local guidance	21/04/2026

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
conestat alfa 2,100units powder (and solvent) for solution for injection (Ruconest®)	745/11	Treatment of acute angioedema attacks in adults and adolescents with hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency.	This medicine is now withdrawn from use/discontinued	21/04/2026
denosumab 60mg/mL solution for injection in pre-filled syringe (Stoboclo®)		In line with current formulary acceptance for the reference product Prolia®.	Routinely available in line with local guidance	21/04/2026
dostarlimab 500mg concentrate for solution for infusion (Jemperli®)	2828	In combination with platinum-containing chemotherapy for the treatment of adult patients with primary advanced or recurrent endometrial cancer and who are candidates for systemic therapy.	Not routinely available as not recommended for use in NHS Scotland, SMC 2828 https://scottishmedicines.org.uk/media/9974/dostarlimab-jemperli-final-march-2026-for-website.pdf	21/04/2026
eszopiclone 1mg, 2mg, 3mg film-coated tablets (Lunivia®)	2922	Treatment of insomnia, in adults, usually for short-term duration.	Not routinely available as not recommended for use in NHS Scotland, SMC 2922 https://scottishmedicines.org.uk/media/9966/eszopiclone-lunivia-non-sub-final-march-2026-for-website.pdf	21/04/2026
etanercept 25mg, 50mg solution for injection in pre-filled pen/syringe (Erelzi®)		In line with current formulary acceptance for etanercept used in the adult rheumatology service.	Routinely available in line with local guidance	21/04/2026
givinostat 8.86mg/mL oral suspension (Duvyzat®)	2856	Treatment of Duchenne muscular dystrophy (DMD) in patients 6 years of age and older who are ambulant when they initiate givinostat treatment; this includes patients who are ambulant when they initiate givinostat and become non-ambulant during treatment.	Routinely available in line with national guidance, SMC 2856 https://scottishmedicines.org.uk/media/9636/givinostat-duvyzat-final-nov-2025-for-website.pdf	21/04/2026
golimumab 50mg, 100mg solution for injection in pre-filled pen/syringe (Gobivaz®)		In line with current formulary acceptance for golimumab used in the adult rheumatology service.	Routinely available in line with local guidance	21/04/2026

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
guanfacine 1mg, 2mg, 3mg, 4mg, 5mg, 6mg, 7mg prolonged-release tablets		For the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents 6 17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective. Guanfacine must be used as a part of a comprehensive ADHD treatment programme, typically including psychological, educational and social measures.	Routinely available in line with local guidance	21/04/2026
guselkumab 100mg, 200mg solution for injection in pre-filled pen, 200mg concentrate for solution for infusion (Tremfya®)	2848	For the treatment of adults with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy, a biologic treatment, or a Janus kinase (JAK) inhibitor.	Routinely available in line with national guidance, SMC 2848 https://scottishmedicines.org.uk/media/9545/guselkumab-tremfya-uc-abb-final-oct-2025-for-website.pdf	21/04/2026
melatonin 1mg, 2mg, 3mg, 4mg, 5mg tablets (Adaflex®)		In line with current formulary acceptance for melatonin. **Restriction:** to patients who cannot swallow solid oral dosage forms.	Routinely available in line with local guidance	21/04/2026
melatonin 1mg/mL oral solution (Ceyesto®)		In line with current formulary acceptance for melatonin. **Restriction:** to patients who cannot swallow solid oral dosage forms and are unable to tolerate Adaflex®.	Decision deferred to future meeting	21/04/2026

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
methylphenidate 20mg, 30mg, 40mg prolonged-release chewable tablets (Tuzulby®)		As part of a comprehensive treatment programme for attention-deficit hyperactivity disorder (ADHD) in children and adolescents 6-17 years old when remedial measures alone prove insufficient. In line with current formulary acceptance for methylphenidate modified release preparations. **Restriction:** patients who: - cannot swallow capsules whole - cannot tolerate capsule beads due to sensory, developmental or oral-motor difficulties - would otherwise require off-label crushed immediate-release methylphenidate or non-formulary liquid formulations, or to move to a second- or third-line ADHD medication option, without adequate trial of first-line methylphenidate	Routinely available in line with local guidance	21/04/2026
nemolizumab 30mg powder and solvent for solution for injection in pre-filled pen (Nemluvio®)	2833	For the treatment of moderate-to-severe atopic dermatitis in combination with topical corticosteroids and/or calcineurin inhibitors in adults and adolescents 12years and older with a body weight of at least 30kg, who are candidates for systemic therapy. **SMC restriction**: for use in patients who have had an inadequate response to an existing systemic immunosuppressant such as ciclosporin, or in whom such treatment is considered unsuitable and where a biologic would otherwise be offered.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	21/04/2026
omalizumab 75mg, 150mg solution for injection in pre-filled pen/syringe (Omlyclo®)		In line with current formulary acceptance for the reference product Xolair®.	Routinely available in line with local guidance	21/04/2026

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
osimertinib 40mg, 80mg film-coated tablets (Tagrisso®)	2815	Treatment of adult patients with locally advanced, unresectable (stage III) non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations and whose disease has not progressed during or following platinum-based chemoradiation therapy.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	21/04/2026
pembrolizumab 25mg/mL concentrate for solution for infusion (Keytruda®)	2829	In combination with chemoradiotherapy (external beam radiation therapy followed by brachytherapy), for the treatment of FIGO 2014 Stage III - IVA locally advanced cervical cancer in adults who have not received prior definitive therapy.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	21/04/2026
procyclidine 10mg/2ml solution for injection ampoules		For the treatment and symptomatic relief of all forms of Parkinson's disease e.g. idiopathic (paralysis agitans), postencephalitic and arteriosclerotic disease. Procyclidine is also used to control troublesome extra-pyramidal symptoms induced by neuroleptic drugs including Pseudo-Parkinsonism, acute dystonic reactions and akathisia.	This medicine is now withdrawn from use/discontinued	21/04/2026
sildenafil 25mg, 50mg tablets	465/24	[Off-label use] for the treatment of digital ulceration in systemic sclerosis in adults.	Routinely available in line with local guidance	21/04/2026
sotatercept 45mg, 60mg powder and solvent for solution for injection (Winrevair®)	2923	In combination with other pulmonary arterial hypertension (PAH) therapies, for the treatment of PAH in adult patients with WHO Functional Class (FC) II to III, to improve exercise capacity. **SMC restriction**: for use in patients with intermediate-low risk status on the European Society of Cardiology (ESC)/European Respiratory Society (ERS) four-strata risk rating system.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	21/04/2026

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
spironolactone 50mg, 100mg tablets	484/25	[Off-label use] for the treatment of adult females with persistent acne. **Restriction:** patients who have failed to respond to two courses of antibiotics, at least 3 months in duration.	Routinely available in line with local guidance	21/04/2026
testosterone undecanoate 1000mg/4 mL solution for injection (Roxadin®)		For male hypogonadism when testosterone deficiency has been confirmed by clinical features and biochemical tests	Routinely available in line with local guidance	21/04/2026